NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 12 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Tarsons Products Q2 FY27 Consolidated Revenue Up 20.8% YoY to ₹123.65 Cr
Tarsons Products announced its Q2 FY27 (quarter ended September 30, 2026) financial results, reporting consolidated revenue from operations of ₹123.65 Cr, representing a 20.8% YoY growth compared to ₹102.33 Cr in Q2 FY26. For H1 FY27, consolidated revenue stood at ₹233.89 Cr versus ₹193.69 Cr in H1 FY26. On a standalone basis, H1 FY27 profit before tax fell sharply to ₹5.13 Cr from ₹13.65 Cr in H1 FY26, largely weighed down by higher depreciation of ₹50.48 Cr (up from ₹37.93 Cr). Total standalone borrowings reached ₹290.48 Cr (long-term ₹115.11 Cr and short-term ₹175.37 Cr) as of September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுTarsons reported its Q2 and H1 FY27 financial results showing top-line revenue expansion alongside margin pressure from newly capitalized assets.
ஏன் இது முக்கியம்Top-line growth of ~21% reflects steady demand and integration of acquisitions, but elevated fixed costs (depreciation up ~33%) continue to compress near-term profitability.
📅 குறுகிய காலம்Market may view top-line growth constructively, but muted bottom-line profitability and high depreciation burden could keep valuation multiples under check.
📈 நீண்ட காலம்Crucial to monitor operating leverage and capacity utilization across newly expanded facilities over the next 2-3 years to restore historical return ratios.
⚠ அபாய எச்சரிக்கைகள்
High depreciation and finance costs depressing standalone profit before tax
Elevated short-term borrowings of ₹175.37 Cr on standalone balance sheet
👀 கவனிக்க வேண்டியவை
Track the ramp-up of the Panchla facility and operating leverage in upcoming quarters to see if top-line growth translates into bottom-line recovery amidst elevated depreciation and interest charges.
Tarsons Q1 FY27 Call: Revenue Up 21% YoY to ₹110 Cr; Capex Ramp-Up Expected in H2
Tarsons Products reported a 21% YoY growth in consolidated revenue to ₹110 crore for Q1 FY27, supported by a 17% rise in domestic sales and a 29% recovery in exports from India. Consolidated cash profit increased 18% YoY to ₹25.6 crore, though bottom-line performance remained suppressed by higher depreciation, finance costs from new capex, and a 25% to 50% spike in raw material input costs. Management noted that growth was driven almost entirely by core products, as incremental capacities contributed negligibly during the quarter. Full commissioning of new facilities is expected in Q2 FY27, with meaningful revenue contributions kicking in from H2 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the detailed transcript of the Q1 FY27 earnings conference call held on August 11, 2026.
ஏன் இது முக்கியம்Provides granular operational clarity on export demand recovery (+29%), raw material inflation magnitude (25-50%), and the timeline for capex commercialization.
Q1 FY27 Consolidated Revenue: ₹110 கோடிQ1 FY27 Standalone Revenue: ₹86 கோடிExport Growth (India): 29%Raw Material Price Inflation: 25% முதல் 50% வரைQ1 FY27 Cash Profit: ₹25.6 கோடி
📅 குறுகிய காலம்Profitability may remain subdued near-term due to elevated depreciation, interest costs, and input cost lag before partial price hikes take full effect.
📈 நீண்ட காலம்Operating leverage from the commissioned Panchla and Amta facilities, coupled with cross-selling synergies via the German subsidiary Nerbe, should support medium-to-long term scale.
⚠ அபாய எச்சரிக்கைகள்
Raw material price inflation (25% to 50%) squeezing gross margins
Near-term margin drag from unabsorbed depreciation and interest on new capex
Government procurement volume decline due to mandatory GEM bidding
👀 கவனிக்க வேண்டியவை
Track margin progression over the next two quarters to see if price hikes offset raw material inflation, along with capacity utilization milestones at the new Panchla and Amta facilities in H2 FY27.
21% Revenue Growth in Q1 FY27; Consolidated Net Loss of ₹1.4 Cr Amid Capex Ramp-up
Tarsons Products reported a 21% YoY increase in consolidated revenue to ₹110.2 cr for Q1 FY27, supported by a 29% rebound in exports and 17% domestic growth. However, the company posted a consolidated net loss of ₹1.4 cr, down from a ₹1.8 cr profit YoY, primarily due to a sharp rise in depreciation (₹24.6 cr standalone) and finance costs linked to the new Amta and Panchla facilities. Standalone EBITDA margins contracted by 310 bps to 28.1% due to raw material price volatility and pre-operating expenses. While top-line growth is robust, the bottom line is currently suppressed by the heavy investment phase, with meaningful revenue contributions from new capacities expected only from FY28 onwards.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into a high-depreciation phase following the capitalization of the Amta and Panchla facilities, leading to a temporary consolidated net loss despite strong sales growth.
ஏன் இது முக்கியம்The financial performance highlights a classic 'capex drag' where massive infrastructure investments (₹150 cr in Amta alone) are hitting the P&L before the revenue from those assets fully scales, testing investor patience regarding long-term margin recovery.
📅 குறுகிய காலம்The stock may face pressure due to the reported consolidated loss and margin contraction, as the market digests the impact of high fixed costs from new facilities.
📈 நீண்ட காலம்Structural growth remains intact if the company successfully ramps up the Panchla and Amta facilities by FY28, potentially leveraging operating scale to restore historical 30%+ EBITDA margins.
⚠ அபாய எச்சரிக்கைகள்
High depreciation and finance costs impacting net profitability
Raw material price volatility affecting gross margins
Execution risk in ramping up new product segments like cell culture
👀 கவனிக்க வேண்டியவை
Investors should monitor the commissioning timeline of the Panchla cell culture lines in Q2 FY27 and the subsequent utilization rates, as the stock's high P/E (116.1) requires a significant earnings recovery once capex stabilizes.
Tarsons Q1 FY27 PAT drops to ₹0.32 Cr; ₹4.14 Cr excess managerial remuneration flagged
Tarsons Products reported a consolidated PAT of ₹0.32 Cr for Q1 FY27, a significant decline from ₹4.18 Cr in the previous quarter, despite revenue growing 35.4% YoY to ₹110.24 Cr. The company disclosed a breach of statutory limits regarding managerial remuneration for FY26, totaling ₹4.14 Cr, which now requires shareholder waiver. Operating margins are under severe pressure as total expenses reached ₹114.75 Cr against a total income of ₹116.22 Cr. The 43rd AGM is scheduled for September 24, 2026, to address these results and the remuneration issue.
உச்சம் நம்பிக்கை
என்ன மாறியதுTarsons has transitioned from a high-margin business to near-zero profitability in Q1 FY27, coupled with a formal disclosure of executive compensation exceeding legal limits.
ஏன் இது முக்கியம்The sharp margin compression and governance oversight regarding executive pay are concerning for a company trading at a high P/E of 116. The high depreciation and finance costs suggest the company is struggling to generate returns on its recent capex in the short term.
Q1 Revenue (Consolidated): ₹110.24 கோடிQ1 PAT (Consolidated): ₹0.32 கோடிExcess Remuneration (FY26): ₹4.14 கோடிRevenue vs TTM Revenue: 26.1%AGM Date: செப்டம்பர் 24, 2026
📅 குறுகிய காலம்The stock is likely to face downward pressure due to the weak earnings performance and the negative sentiment surrounding the managerial remuneration breach.
📈 நீண்ட காலம்Long-term recovery depends on the company's ability to utilize its expanded capacity at Panchla and Amta to offset high fixed costs and improve margins back toward historical levels.
⚠ அபாய எச்சரிக்கைகள்
Governance risk due to excess managerial remuneration
Severe margin compression
High finance costs relative to profitability
👀 கவனிக்க வேண்டியவை
Investors should monitor the shareholder vote on the managerial remuneration waiver at the AGM and track the ramp-up of the Panchla facility, which is critical for improving operating leverage from FY27.
Tarsons Q1 FY27: Revenue Up 20.6% YoY to ₹110.2 Cr; Consolidated PAT Drops to ₹0.08 Cr
Tarsons Products reported a 20.6% YoY increase in consolidated revenue to ₹110.24 Cr for Q1 FY27, up from ₹91.36 Cr. However, consolidated Profit After Tax (PAT) plummeted to just ₹0.08 Cr from ₹1.78 Cr in the year-ago period, primarily due to high fixed costs. Depreciation and finance costs surged to ₹27.02 Cr and ₹6.26 Cr respectively, likely reflecting the capitalization of new facilities. Additionally, two unreviewed subsidiaries reported a combined loss of ₹1.77 Cr, significantly weighing down the consolidated performance compared to the standalone PAT of ₹0.68 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுTarsons has transitioned to a higher fixed-cost structure following recent expansions, resulting in significant margin compression despite steady revenue growth.
ஏன் இது முக்கியம்The sharp drop in PAT indicates that the company is currently struggling with operating leverage; the high depreciation and interest costs from new investments are currently outpacing the incremental revenue gains.
Consolidated Revenue (Q1 FY27): ₹110.24 கோடிConsolidated PAT (Q1 FY27): ₹0.08 கோடிDepreciation vs Revenue: 24.5%Excess Managerial Remuneration (FY26): ₹4.14 கோடிRevenue vs TTM Revenue: 26.1%
📅 குறுகிய காலம்The stock is likely to face negative pressure in the short term as the market reacts to the near-zero consolidated profitability and the drag from loss-making subsidiaries.
📈 நீண்ட காலம்Long-term value depends on the company's ability to scale operations at the Panchla and Amta facilities to achieve operating leverage and successfully integrate the Nerbe group acquisition.
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization and ramp-up timeline of the Panchla facility, as the current high depreciation and interest costs require significant volume growth to restore margins. Watch for the turnaround of international subsidiaries and the outcome of the AGM vote on managerial remuneration.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Tarsons Products Infuses EUR 552,000 in Singapore Subsidiary for Debt Repayment
Tarsons Products Limited has completed the second tranche of its planned EUR 3,000,000 equity infusion into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd. In this tranche, the company invested EUR 552,000 by subscribing to 184 equity shares at EUR 3,000 per share. This follows an earlier investment of EUR 300,000 in April 2026. The funds are specifically designated for the subsidiary to repay bank loans, cover interest costs, and meet general operational requirements in Singapore.
முக்கிய அம்சங்கள்
Completed second tranche investment of EUR 552,000 in Tarsons Life Science Pte. Ltd., Singapore.Subscribed to 184 equity shares at a nominal value of EUR 3,000 per share on June 03, 2026.Total approved equity infusion for the subsidiary aggregates to EUR 3,000,000.Proceeds will be utilized for bank loan repayment, interest payments, and general corporate purposes.The subsidiary is a non-operating financial holding company with nil turnover reported for FY 2025-26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the total capital allocation to this Singapore SPV and observe if these investments lead to future international acquisitions or operational growth, as current funds are primarily servicing debt.
Tarsons Products Q4 FY26 Revenue Hits Record ₹121 Cr; FY26 Cash PAT Grows 21.5% to ₹112 Cr
Tarsons Products reported its highest-ever quarterly revenue of ₹121 crores in Q4 FY26, marking a 7.4% YoY growth, while FY26 consolidated revenue reached ₹426 crores. Despite a 13.4% decline in exports due to Middle East geopolitical tensions, the domestic business grew strongly by 11.7%. Reported PAT was significantly impacted by ₹87 crores in depreciation and higher interest costs from new capex, but Cash PAT showed robust growth of 21.5% YoY to reach ₹112 crores. Management expects the massive capex program to be fully commissioned in H1 FY27, leading to improved operating leverage.
முக்கிய அம்சங்கள்
Consolidated revenue for Q4 FY26 grew 7.4% YoY to ₹121 crores, the highest quarterly performance to date.Domestic revenue grew by 11.7% in Q4, significantly outperforming the industry growth of 3%.FY26 Cash PAT increased by 21.5% to ₹112 crores, reflecting strong underlying cash flow despite high depreciation charges of ₹87 crores.Export revenue declined 13.4% in Q4 due to supply chain disruptions and container shortages linked to the Middle East crisis.The company's large-scale capex program is in its final phase, with full commissioning expected in H1 FY27.
👀 கவனிக்க வேண்டியவை
Investors should look past the depressed reported PAT, which is currently weighed down by high depreciation from new plants, and focus on the 21.5% growth in Cash PAT. The key monitorable is the revenue ramp-up from the newly commissioned Amta and Panchla facilities in FY27 to trigger operating leverage.
Tarsons Products FY26 Revenue Up 8% to ₹423 Cr; Adjusted Cash PAT Grows 21% to ₹112 Cr
Tarsons Products reported a consolidated revenue growth of 8% YoY to ₹422.5 crore for FY26, supported by a 14% growth in its subsidiary Nerbe and 7% domestic growth. While reported Adjusted PAT declined by 48.1% to ₹15.5 crore due to high depreciation and finance costs from new facility capitalization, Adjusted Cash PAT (PAT + Depreciation) grew by a robust 21.4% to ₹112 crore. EBITDA margins saw a contraction to 27.9% from 30.6% in the previous year, primarily due to rising raw material prices and pre-operative expenses for new plants. The company expects significant revenue contributions from its newly commissioned Panchla and Amta facilities starting in FY27.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 increased 8% YoY to ₹422.5 crore, with Q4FY26 revenue up 7% to ₹120.9 crore.Adjusted Cash PAT grew 21.4% YoY to ₹112 crore, indicating strong operational cash generation despite accounting profit pressure.Reported Adjusted PAT fell 48.1% to ₹15.5 crore, heavily impacted by ₹96.5 crore in depreciation and ₹22.5 crore in finance costs.EBITDA margins compressed to 27.9% in FY26 from 30.6% in FY25 due to input cost pressure and expansion overheads.New manufacturing facilities at Panchla and Amta have commenced commercial supplies, with full commissioning expected by H1FY27.
👀 கவனிக்க வேண்டியவை
Investors should look past the suppressed net profit, which is currently hit by non-cash depreciation from major CAPEX, and focus on the 21% growth in Cash PAT. The key monitorable is the revenue ramp-up and margin recovery as the new capacities at Panchla and Amta reach optimal utilization in FY27.
Tarsons Products Limited has approved its audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The company's statutory auditors, Price Waterhouse Chartered Accountants LLP, have issued an unmodified opinion, signifying the reliability of the financial statements. Additionally, the board has re-appointed Grant Thornton Bharat LLP as the internal auditors for the financial year 2026-27. The consolidated results encompass the performance of its international subsidiaries, including the German entities Nerbe plus GmbH and Nerbe R&D GmbH.
முக்கிய அம்சங்கள்
Board approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.Statutory auditors Price Waterhouse issued an unmodified opinion on the financial results.Grant Thornton Bharat LLP re-appointed as Internal Auditors for the 2026-27 financial year.Consolidated results include 100% ownership of subsidiaries in Singapore and Germany (Nerbe plus group).
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial statements to assess the growth trajectory and margin performance following the integration of German acquisitions. The unmodified auditor opinion is a positive indicator of financial transparency and governance.
Tarsons Appoints Mani Kalyan Dusi as Head of Revenue for India & APAC
Tarsons Products Limited has appointed Mr. Mani Kalyan Dusi as the Head of Revenue for India and the APAC region, effective on or before May 20, 2026. Mr. Dusi joins with over 18 years of experience in the life sciences and pharmaceutical sectors, having held senior roles at global giants like Merck Life Science and Thermo-Fisher Scientific. His expertise in commercial leadership and go-to-market strategies is expected to drive growth in key regional markets. This appointment strengthens the company's senior management team as it looks to expand its footprint in the APAC region.
முக்கிய அம்சங்கள்
Mr. Mani Kalyan Dusi appointed as Head - Revenue (India & APAC) starting May 20, 2026Brings over 18 years of experience from industry leaders Merck Life Science and Thermo-Fisher ScientificExpertise includes P&L management, strategic marketing, and digital enablement in the life sciences sectorEducational background includes an M.Sc. in Biochemistry and executive education from INSEADThe role is designated as Senior Management Personnel (SMP) to lead regional business development
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in professionalizing management and strengthening commercial capabilities. Monitor the company's revenue growth in the APAC region over the next 4-6 quarters to assess the impact of this leadership change.
Tarsons Products Infuses EUR 300,000 in Singapore Subsidiary for Debt Servicing
Tarsons Products Limited has completed an equity investment of EUR 300,000 in its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd. This transaction is part of a larger EUR 3,000,000 capital infusion plan previously approved by the Board in February 2026. The funds are specifically allocated for quarterly bank loan repayments, interest payments, and general corporate purposes within the subsidiary. The Singapore entity is a non-operating financial holding company and has reported zero turnover since its incorporation in November 2023.
முக்கிய அம்சங்கள்
Completed equity infusion of EUR 300,000 by subscribing to 100 shares at EUR 3,000 each.Part of a total board-approved investment limit of EUR 3,000,000 for the Singapore subsidiary.Funds utilized for quarterly repayment of bank loans and interest obligations in Singapore.The subsidiary, Tarsons Life Science Pte. Ltd., functions as an SPV with nil turnover for FY 2025-26.The investment ensures the subsidiary meets its financial and operational expenses without change in ownership.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine financial management move to service international debt obligations. Monitor the company's consolidated debt levels and the performance of any assets held under this Singapore SPV.
Tarsons Products Appoints M&A Expert Vinesh Mohan Kriplani as Independent Director for 5-Year Term
Tarsons Products Limited has confirmed the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director for a five-year term, effective February 06, 2026, following shareholder approval. Mr. Kriplani is a seasoned professional with over 29 years of experience in corporate taxation and M&A, currently leading these functions at the Serum Institute of India. His background includes senior leadership roles at Big Four firms like EY, KPMG, and PwC, where he specialized in cross-border transactions and strategic growth. This appointment is expected to significantly bolster the company's board-level expertise in governance and financial strategy.
முக்கிய அம்சங்கள்
Appointment of Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director for a 5-year term.Mr. Kriplani brings over 29 years of experience in international taxation, M&A, and corporate restructuring.He currently leads M&A and international tax matters for the Poonawalla Group through the Serum Institute of India.The appointment was ratified by shareholders via postal ballot with the results declared on April 08, 2026.Mr. Kriplani previously served as a Senior Partner at EY India and is a co-founder of Transaction Square LLP.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for corporate governance and strategic oversight. The addition of an M&A and tax specialist from a major healthcare group may indicate a focus on future inorganic growth or complex international expansions.
CARE Reaffirms Tarsons Products Credit Ratings; Enhances Short-Term Facilities to ₹84 Crore
CARE Ratings has reaffirmed the credit ratings for Tarsons Products Limited across its various bank loan facilities. The long-term rating for ₹500.73 crores of facilities remains at 'CARE A; Stable', while short-term ratings are maintained at 'CARE A1'. The company also saw an enhancement in its short-term bank facility limits from ₹39.00 crores to ₹84.00 crores, alongside a new assignment of ₹4.00 crores for additional short-term facilities. This reaffirmation reflects the company's stable financial profile and maintained creditworthiness in the eyes of the rating agency.
முக்கிய அம்சங்கள்
Long-term bank facilities of ₹500.73 crores reaffirmed at CARE A; StableShort-term bank facilities of ₹84.00 crores reaffirmed at CARE A1, enhanced from ₹39.00 croresNew short-term bank facility of ₹4.00 crores assigned a CARE A1 ratingLong-term/Short-term facilities of ₹24.00 crores reaffirmed at CARE A; Stable / CARE A1
👀 கவனிக்க வேண்டியவை
The reaffirmation of ratings suggests financial stability; investors should continue to monitor the company's debt levels and execution of its expansion plans.
Tarsons Products Q3 FY26: Revenue Up 12.8%, Adjusted Cash PAT Surges 38.6% YoY
Tarsons Products reported a consolidated revenue of ‑108 crores for Q3 FY26, a 12.8% YoY growth, while adjusted cash PAT rose significantly by 38.6% to ‑31.4 crores. Reported PAT was impacted by higher depreciation of ‑60.6 crores for 9M FY26 following the partial capitalization of the Panchla facility. Management highlighted a revenue potential of over ‑150 crores from the new bioprocess container line at full capacity. With cell culture capex expected to commercialize in Q4 FY26, the company anticipates stronger revenue momentum in FY27.
முக்கிய அம்சங்கள்
Consolidated revenue grew 12.8% YoY to ‑108 crores in Q3 FY26.Adjusted Cash PAT increased by 38.6% YoY to ‑31.4 crores, reflecting strong operational performance.Standalone EBITDA margin stood at 34.7%, while consolidated EBITDA margin was 29.2%.New bioprocess container capacity has a potential revenue generation of ‑150+ crores at full utilization.Depreciation increased to ‑60.6 crores for 9M FY26 due to the ‑600 crore Panchla facility expansion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the Panchla facility and the adoption of new cell culture products in FY27. Focus on Cash PAT and EBITDA as primary metrics while the company navigates high depreciation from its major capex cycle.
Tarsons to Infuse EUR 3M in Singapore Subsidiary and Appoints New Independent Director
Tarsons Products Limited has approved an equity infusion of EUR 3 million into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and loan repayments. The board also announced the appointment of Mr. Vinesh Mohan Kriplani, a seasoned M&A and tax expert from the Poonawalla Group, as an Independent Director for a five-year term. This follows the resignation of Mr. Girish Paman Vanvari from the board and its committees. The capital infusion into the Singapore entity is scheduled to be completed in quarterly tranches by March 2027.
முக்கிய அம்சங்கள்
Approved equity infusion of EUR 3 million into Singapore-based subsidiary Tarsons Life Science Pte. Ltd.Capital infusion to be completed in quarterly tranches on or before March 31, 2027.Appointed Mr. Vinesh Mohan Kriplani, a veteran with 29+ years of experience in M&A and taxation, as Independent Director.Mr. Girish Paman Vanvari resigned as Independent Director and Chairperson of Audit and Risk committees.The Singapore subsidiary reported nil turnover for the financial years 2023-24 and 2024-25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the strategic utilization of the EUR 3 million infusion in the Singapore subsidiary, which is currently a non-operating entity. The addition of a high-profile M&A expert to the board is a positive sign for future corporate governance and strategic growth.
Tarsons Q3FY26 Revenue up 13% to ₹108 Cr; Adjusted Cash PAT grows 39% YoY
Tarsons Products reported a 12.8% YoY growth in consolidated revenue for Q3FY26, reaching ₹107.9 crores. While EBITDA grew by 6.3% to ₹31.5 crores, the bottom line (Adjusted PAT) for 9MFY26 saw a 41.4% decline due to high depreciation and finance costs from new facility capitalizations. However, Adjusted Cash PAT showed robust growth of 38.6% for the quarter, indicating strong underlying cash generation. The company expects its major capacity expansions at Panchla and Amta to be commissioned in Q4 FY26, which should drive future revenue.
முக்கிய அம்சங்கள்
Consolidated Q3FY26 Revenue rose 12.8% YoY to ₹107.9 crores.Adjusted Cash PAT (PAT + Depreciation) grew 38.6% YoY to ₹31.4 crores in Q3FY26.9MFY26 EBITDA margins improved to 27.7% from 26.3% YoY.Consolidated 9MFY26 revenue mix stands at 52% Domestic and 48% Overseas.Final phase of capacity expansion is on track for commissioning in Q4 FY26.
👀 கவனிக்க வேண்டியவை
The stock is currently in a high-capex phase where accounting profits are suppressed by depreciation; investors should monitor the revenue scale-up from new plants in FY27.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
